Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (GB:0HD2)
LSE:0HD2
0HD2 Stock Chart & Stats
$479.55
-$1.89(-0.80%)
At close: 4:00 PM EST
$479.55
-$1.89(-0.80%)
Day’s Range― - ―
52-Week Range$209.75 - $495.20
Previous CloseN/A
Volume1.06K
Average Volume (3M)245.00
Market Cap
$62.38B
Enterprise Value$42.48B
Total Cash (Recent Filing)$2.86B
Total Debt (Recent Filing)$1.30B
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Feb 12, 2026EPS EstimateN/A
Last Dividend Ex-Date
Mar 15, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)1.91
Shares Outstanding131,079,010
10 Day Avg. Volume393
30 Day Avg. Volume245
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue17.25
Enterprise Value/Gross Profit20.63
Enterprise Value/Ebitda-248.52
Forecast
1Y Price Target
$478.96Price Target Upside-0.12% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering26
Bulls Say, Bears Say
Bulls Say
FDA Guidance BenefitsAlnylam Pharmaceuticals stands to benefit from the FDA's draft guidances, which broaden flexibility in clinical trial design and expand the role of real-world evidence across genetic medicines.
Price Target IncreaseThe price target for Alnylam Pharmaceuticals is raised to $475, reflecting a positive outlook on the stock.
Sales PerformanceMonthly sales analysis suggests upside to 3Q25 Amvuttra estimates, indicating strong sales performance.
Bears Say
Valuation ConcernsQuestions on ALNY’s valuation at current levels and the upside from here indicate concerns about the sustainability of the launch momentum.
Zilebesiran LimitationsPhysicians were relatively underwhelmed by the magnitude of effect in the overall population for zilebesiran in hypertension, indicating potential limitations.
Alnylam Pharma News
0HD2 FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest share price was $209.75 and its highest was $495.20 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Alnylam Pharmaceuticals’s market cap is $62.38B.
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Feb 12, 2026 which is in 105 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on Oct 30, 2025. The company reported $1.91 earnings per share for the quarter, beating the consensus estimate of $0.561 by $1.349.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Overvalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Alnylam Pharmaceuticals dividends here
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 131,079,010 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of $1.91 in its last earnings report, beating expectations of $0.561. Following the earnings report the stock price went up 13.812%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Currently, no hedge funds are holding shares in GB:0HD2
Alnylam Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$478.96 (-0.12% Downside)
$478.96 (-0.12% Downside)
Blogger Sentiment
Bullish
GB:0HD2 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $14.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.87%
12-Months-Change
Fundamentals
Return on Equity
-257.82%
Trailing 12-Months
Asset Growth
13.88%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
0HD2 Company Deck
0HD2 Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Alnylam Q2 2025 highlighted strong commercial performance and successful product launches, particularly for AMVUTTRA in ATTR-CM, leading to an upgraded financial outlook. Despite some decreases in collaboration revenue and product sales margins, the overall sentiment remains highly positive due to the robust growth and positive future guidance.View all GB:0HD2 earnings summaries0HD2 Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
0HD2 Stock 12 Month Forecast
Average Price Target
$478.96
▼(-0.12% Downside)
Technical Analysis
Options Prices
Currently, No data available
---